Go Pro
→ Something dark just appeared in America (From Porter & Company) (Ad)tc pixel Free MRKR Stock Alerts

Marker Therapeutics (MRKR) Financials

Marker Therapeutics logo
$1.14 -0.09 (-6.91%)
Closing price 08/5/2026 03:58 PM Eastern
Extended Trading
$1.14 -0.01 (-0.44%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Marker Therapeutics

Annual Income Statements for Marker Therapeutics

This table shows Marker Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -30 0.00 0.00 -11 -21 -29 -42 -30 -8.24 -11 -12
Consolidated Net Income / (Loss)		 -31 0.00 0.00 -11 -21 -29 -42 -30 -8.24 -11 -12
Net Income / (Loss) Continuing Operations		 -30 0.00 0.00 -11 -21 -29 -42 -20 -14 -11 -12
Total Pre-Tax Income 		-30 0.00 0.00 -11 -21 -29 -42 -20 -14 -11 -12
Total Operating Income		 -3.37 0.00 0.00 -11 -23 -29 -39 -20 -15 -11 -13
Total Gross Profit		 0.00 0.00 0.00 0.18 0.21 0.47 1.24 3.51 3.31 6.59 3.55
Total Revenue		 0.00 0.00 0.00 0.18 0.21 0.47 1.24 3.51 3.31 6.59 3.55
Operating Revenue		 - - - 0.18 0.21 0.47 1.24 3.51 3.31 6.59 3.55
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 3.37 0.00 0.00 12 23 29 41 23 18 18 16
Selling, General & Admin Expense		 3.18 - - 6.41 9.98 10 13 11 7.48 4.24 4.18
Research & Development Expense		 0.19 - - 5.25 13 19 28 12 10 13 12
Other Special Charges / (Income)		 - - - - - - - - - 0.00 0.45
Total Other Income / (Expense), net		 -27 0.00 0.00 0.50 1.10 0.18 -2.40 0.02 0.54 0.44 0.71
Interest & Investment Income		 - - - 0.00 1.08 0.15 0.01 0.25 0.54 0.44 0.59
Other Income / (Expense), net		 0.00 - - 0.01 0.02 0.03 -2.41 -0.23 - 0.00 0.12
Income Tax Expense		 - - - - - - - 0.00 0.00 0.05 -0.02
Basic Earnings per Share		 ($2.00) ($9.30) ($0.36) ($1.16) ($0.47) ($0.61) ($5.47) ($3.58) ($0.94) ($1.19) ($0.79)
Weighted Average Basic Shares Outstanding		 15.47M 3.66M 6.89M 9.45M 45.59M 47.04M 7.65M 8.35M 8.81M 8.98M 15.31M
Diluted Earnings per Share		 ($2.00) ($9.30) ($0.72) ($1.16) ($0.47) ($0.61) ($5.47) ($3.58) ($0.94) ($1.19) ($0.79)
Weighted Average Diluted Shares Outstanding		 15.47M 3.66M 7.42M 9.45M 45.59M 47.04M 7.65M 8.35M 8.81M 8.98M 15.31M
Weighted Average Basic & Diluted Shares Outstanding		 15.47M 43.95M 8.44M 9.45M 45.59M 47.04M 83.08M 8.80M 8.90M 10.71M 16.67M

Quarterly Income Statements for Marker Therapeutics

This table shows Marker Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -2.98 -2.80 -2.39 -2.19 -2.31 -3.84 -4.45 -4.02 -2.00 -1.70 -3.18
Consolidated Net Income / (Loss)		 -2.98 -2.80 -2.39 -2.19 -2.31 -3.84 -4.45 -4.02 -2.00 -1.70 -3.18
Net Income / (Loss) Continuing Operations		 -2.98 -2.74 0.00 -2.19 -2.31 -6.23 -4.45 -4.02 -2.00 -6.15 -3.18
Total Pre-Tax Income 		-2.98 -2.74 -2.39 -2.19 -2.31 -3.79 -4.45 -4.13 -2.00 -6.05 -3.19
Total Operating Income		 -3.20 -2.94 -2.55 -2.31 -2.40 -3.86 -4.96 -4.26 -2.14 -1.88 -4.07
Total Gross Profit		 0.26 1.06 1.24 1.17 1.93 2.25 0.00 0.86 1.23 1.10 0.00
Total Revenue		 0.26 1.06 1.24 1.17 1.93 2.25 0.00 0.86 1.23 1.10 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 3.46 3.99 3.79 3.48 4.33 6.11 4.96 5.12 3.37 2.99 4.07
Selling, General & Admin Expense		 1.41 1.38 1.22 1.14 0.85 1.03 1.37 0.95 1.02 0.85 1.23
Research & Development Expense		 2.04 2.62 2.58 2.34 3.47 5.09 3.14 4.18 2.35 2.14 2.84
Other Operating Expenses / (Income)		 - - - - - - 0.45 0.00 - - 0.00
Total Other Income / (Expense), net		 0.22 0.20 0.16 0.12 0.09 0.07 0.51 0.13 0.14 0.28 0.88
Interest & Investment Income		 0.22 0.20 0.16 0.12 0.09 0.07 0.16 0.13 0.14 0.17 0.13
Other Income / (Expense), net		 - - - - - - 0.35 - - - 0.75
Other Gains / (Losses), net		 - - - 0.00 0.00 - 0.00 0.12 0.00 - 0.01
Basic Earnings per Share		 ($0.34) ($0.32) ($0.27) ($0.25) ($0.26) ($0.43) ($0.40) ($0.29) ($0.12) $0.02 ($0.16)
Weighted Average Basic Shares Outstanding		 8.83M 8.81M 8.90M 8.92M 8.92M 8.98M 11.11M 13.96M 16.76M 15.31M 19.31M
Diluted Earnings per Share		 ($0.34) ($0.32) ($0.27) ($0.25) ($0.26) ($0.43) ($0.40) ($0.29) ($0.12) $0.02 ($0.16)
Weighted Average Diluted Shares Outstanding		 8.83M 8.81M 8.90M 8.92M 8.92M 8.98M 11.11M 13.96M 16.76M 15.31M 19.31M
Weighted Average Basic & Diluted Shares Outstanding		 8.89M 8.90M 8.92M 8.92M 8.92M 10.71M 11.31M 12.94M 16.67M 16.67M 16.67M

Annual Cash Flow Statements for Marker Therapeutics

This table details how cash moves in and out of Marker Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.09 6.43 1.27 -2.72 -18 -23 22 -32 3.33 4.08 -2.15
Net Cash From Operating Activities		 -2.19 -4.34 -6.51 -8.44 -18 -20 -27 -27 -16 -11 -12
Net Cash From Continuing Operating Activities		 -1.29 -4.34 -6.51 -8.44 -18 -20 -27 -22 -10 -11 -12
Net Income / (Loss) Continuing Operations		 -31 -34 -2.46 -11 -21 -29 -42 -20 -14 -11 -12
Consolidated Net Income / (Loss)		 -31 -34 -2.46 -11 -21 -29 -42 -30 -8.24 -11 -12
Non-Cash Adjustments To Reconcile Net Income		 29 1.74 1.63 2.25 5.17 5.23 5.96 3.03 0.86 0.75 0.36
Changes in Operating Assets and Liabilities, net		 0.31 28 -5.68 0.30 -2.31 2.37 5.47 -4.76 2.85 -0.93 -0.21
Net Cash From Investing Activities		 0.00 0.00 0.00 0.00 -0.37 -9.25 -3.13 -4.95 19 0.00 0.00
Net Cash From Continuing Investing Activities		 0.00 0.00 0.00 0.00 -0.37 -9.25 -3.13 0.00 0.00 0.00 0.00
Net Cash From Financing Activities		 2.28 11 7.78 5.72 0.82 6.74 53 0.20 1.11 15 9.86
Net Cash From Continuing Financing Activities		 2.28 11 7.78 5.72 0.82 6.74 53 0.20 1.11 15 9.86
Issuance of Common Equity		 1.88 2.46 2.33 5.41 0.00 6.19 53 0.20 1.01 15 9.86
Other Financing Activities, net		 - 8.45 5.50 0.62 0.82 0.55 0.00 0.00 0.09 0.06 0.00

Quarterly Cash Flow Statements for Marker Therapeutics

This table details how cash moves in and out of Marker Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -0.65 -2.36 -3.79 -3.52 1.20 10 -5.50 -1.88 7.13 -1.90 -1.40
Net Cash From Operating Activities		 -1.13 -2.37 -3.84 -3.57 1.20 -4.70 -5.50 -1.88 -2.74 -1.90 -1.40
Net Cash From Continuing Operating Activities		 -0.87 -2.30 -3.84 -3.57 1.20 -4.70 -5.50 -1.88 -2.74 -1.90 -1.40
Net Income / (Loss) Continuing Operations		 -2.98 -2.74 -2.39 -2.19 -2.31 -3.84 -4.45 -4.02 -2.00 -1.70 -3.18
Consolidated Net Income / (Loss)		 -2.98 -2.80 -2.39 -2.19 -2.31 -3.84 -4.45 -4.02 -2.00 -1.70 -3.18
Non-Cash Adjustments To Reconcile Net Income		 0.18 0.14 0.08 -0.33 0.27 0.73 0.02 -0.78 0.19 0.58 0.42
Changes in Operating Assets and Liabilities, net		 1.94 0.29 -1.52 -1.04 3.23 -1.60 -1.08 2.92 -0.92 -0.78 1.36
Net Cash From Investing Activities		 - - 0.00 - - - 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 - - 0.00 - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 0.48 0.01 0.05 0.04 0.00 15 0.00 0.00 9.86 - 0.00
Net Cash From Continuing Financing Activities		 0.48 0.01 0.05 0.04 0.00 15 0.00 0.00 9.86 - 0.00
Other Financing Activities, net		 0.08 0.01 0.05 0.01 0.00 0.00 0.00 0.00 - - 0.00

Annual Balance Sheets for Marker Therapeutics

This table presents Marker Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.22 6.65 7.92 5.18 46 46 68 34 17 22 19
Total Current Assets		 0.22 6.65 7.92 5.18 45 24 46 17 17 22 19
Cash & Equivalents		 0.14 6.58 7.85 5.13 44 21 42 12 15 19 16
Restricted Cash		 - - - - - - 1.15 - - 0.00 0.97
Accounts Receivable		 - - - - 0.00 1.00 0.00 2.40 1.03 2.35 1.37
Prepaid Expenses		 0.08 0.07 0.07 0.05 1.53 2.06 2.48 1.85 0.99 0.48 0.66
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 0.87 21 22 18 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 0.22 6.65 7.92 5.18 46 46 68 34 17 22 19
Total Liabilities		 1.25 28 1.74 1.52 2.27 18 24 15 3.07 3.46 2.27
Total Current Liabilities		 1.25 28 1.74 1.52 1.99 6.40 13 7.78 3.07 3.46 2.27
Accounts Payable		 0.69 0.97 1.22 1.51 1.76 6.01 11 2.52 1.75 1.75 1.30
Current Deferred Revenue		 - - - - - - 1.15 - - 0.00 0.97
Other Current Liabilities		 0.52 27 0.51 0.01 0.24 0.39 0.62 0.00 1.33 1.71 0.00
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.28 12 11 7.04 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 - - - - 0.28 12 11 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -1.02 -21 6.18 3.66 44 27 44 20 14 19 17
Total Preferred & Common Equity		 -1.02 -21 6.18 3.66 44 27 44 20 14 19 17
Preferred Stock		 - - - - 0.00 - - 0.00 0.00 0.00 0.00
Total Common Equity		 -1.02 -21 6.18 3.66 44 27 44 20 14 19 17
Common Stock		 85 112 152 161 372 384 442 448 450 466 476
Retained Earnings		 -86 -134 -146 -157 -328 -356 -398 -428 -436 -447 -459

Quarterly Balance Sheets for Marker Therapeutics

This table presents Marker Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 19 14 12 11 17 15 22 17
Total Current Assets		 19 14 12 11 17 15 22 17
Cash & Equivalents		 17 11 7.80 9.00 14 10 18 15
Restricted Cash		 - - - - - 1.35 1.35 0.72
Accounts Receivable		 0.08 1.85 2.49 0.74 2.46 1.67 1.67 1.38
Prepaid Expenses		 1.93 0.92 1.38 1.17 0.84 1.28 1.13 0.42
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 19 14 12 11 17 15 22 17
Total Liabilities		 2.78 2.30 1.97 3.46 2.50 4.28 3.35 3.64
Total Current Liabilities		 2.78 2.30 1.97 3.46 2.50 4.28 3.35 3.64
Accounts Payable		 2.30 1.95 1.68 2.56 2.09 2.27 1.66 1.91
Current Deferred Revenue		 0.11 - - - - 1.35 1.35 0.72
Other Current Liabilities		 0.37 0.35 0.29 0.90 0.41 0.66 0.33 1.00
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 17 12 9.70 7.45 14 10 18 14
Total Preferred & Common Equity		 17 12 9.70 7.45 14 10 18 14
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 17 12 9.70 7.45 14 10 18 14
Common Stock		 450 450 451 451 466 466 476 476
Retained Earnings		 -433 -439 -441 -443 -451 -455 -457 -462

Annual Metrics And Ratios for Marker Therapeutics

This table displays calculated financial ratios and metrics derived from Marker Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 129,237,524.00 8,379,101.00 10,539,057.00 45,370,695.00 45,723,414.00 48,025,102.00 83,078,675.00 83,599,187.00 8,889,020.00 8,923,490.00 16,673,127.00
DEI Adjusted Shares Outstanding		 12,923,752.00 837,910.00 1,053,906.00 4,537,069.00 4,572,341.00 4,802,510.00 8,307,867.00 8,359,919.00 8,889,020.00 8,923,490.00 16,673,127.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -10.42 - -4.69 -5.98 -5.04 -3.58 -0.93 -1.20 -0.73
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 12.53% 0.00% 118.95% 166.01% 182.96% -5.76% 99.06% -46.19%
EBITDA Growth		 100.00% 0.00% 0.00% -1,191.66% 85.01% -24.99% -39.39% 48.29% 27.18% 23.75% -14.88%
EBIT Growth		 100.00% 0.00% 0.00% -1,191.66% 84.81% -28.18% -45.16% 52.19% 27.18% 23.75% -14.88%
NOPAT Growth		 100.00% 0.00% 0.00% -1,190.69% 89.36% -28.22% -36.67% 49.87% 26.32% 23.75% -15.94%
Net Income Growth		 100.00% 0.00% 0.00% -1,247.25% 0.00% -33.97% -45.89% 28.53% 72.48% -30.28% -13.35%
EPS Growth		 -365.00% 92.26% -61.11% -568.10% 0.00% -29.79% -45.89% 28.53% 73.74% -26.60% 33.61%
Operating Cash Flow Growth		 -98.59% -49.88% -29.64% -71.57% 0.00% -9.57% -36.16% 1.13% 39.05% 33.64% -10.12%
Free Cash Flow Firm Growth		 488.86% -198.03% 68.63% -1,161.61% 87.53% -41.79% 14.98% 31.79% 50.86% -10.65% -14.66%
Invested Capital Growth		 -2,355.35% 94.04% 11.46% -63.54% 107.58% 3,187.46% -91.85% 254.33% -161.21% 40.12% 61.20%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -47.05% 0.00% 0.00% 0.00% -12.08% 9.87% 22.15% -24.46%
EBITDA Q/Q Growth		 100.00% 0.00% 0.00% -616.84% 0.00% -4,120.08% -9.34% 34.68% -38.28% -9.06% 14.09%
EBIT Q/Q Growth		 100.00% 0.00% 0.00% -616.84% 0.00% 0.00% -9.58% 34.68% -38.28% -9.06% 14.09%
NOPAT Q/Q Growth		 100.00% 0.00% 0.00% -619.90% 0.00% 0.00% -3.29% 35.44% -38.28% -9.06% 13.30%
Net Income Q/Q Growth		 100.00% 0.00% 0.00% -813.44% 0.00% 0.00% -3.09% 16.48% 11.34% -10.67% 14.93%
EPS Q/Q Growth		 -314.78% 0.00% 0.00% -500.78% 0.00% 0.00% -3.09% 16.48% 10.48% -9.17% 7.06%
Operating Cash Flow Q/Q Growth		 -4.37% -16.10% -9.40% -34.13% 0.00% -4.94% 2.31% -5.67% 19.32% -27.24% 18.92%
Free Cash Flow Firm Q/Q Growth		 -12.12% 0.00% 0.00% 0.00% -511.33% -514.36% 17.09% 32.63% -255.06% -29.19% 17.47%
Invested Capital Q/Q Growth		 16.58% 0.00% 0.00% 33.14% 130.60% 64.57% -86.35% -61.77% -38.10% 59.10% 55.59%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% -6,268.05% -71,949.49% -10,424.41% -5,951.16% -3,118.44% -569.91% -440.37% -168.69% -360.14%
Operating Margin		 0.00% 0.00% -6,271.05% -71,930.07% -10,567.28% -6,188.25% -3,179.32% -563.28% -440.37% -168.69% -363.45%
EBIT Margin		 0.00% 0.00% -6,268.05% -71,949.49% -10,558.84% -6,181.61% -3,373.14% -569.91% -440.37% -168.69% -360.14%
Profit (Net Income) Margin		 0.00% 0.00% -5,999.09% -71,826.32% -10,050.92% -6,149.74% -3,372.68% -851.87% -248.76% -162.82% -342.96%
Tax Burden Percent		 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 151.35% 58.66% 100.47% 99.88%
Interest Burden Percent		 0.00% 0.00% 95.71% 99.83% 95.19% 99.48% 99.99% 98.76% 96.30% 96.07% 95.35%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -654.96% -852.86% -1,249.03% -3,041.67% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% -628.95% -808.93% -1,196.63% -3,053.61% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 574.58% 735.44% 1,154.89% 2,992.72% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00% -223.15% -469.72% -97.21% -80.37% -117.42% -94.14% -48.95% -65.81% -68.81%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -10,071.90% -843.15% -683.00% -1,360.99% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -175.16% -440.29% -97.11% -62.75% -73.64% -39.05% -56.57% -56.80% -62.16%
Return on Assets (ROA)		 0.00% 0.00% -167.64% -439.54% -92.44% -62.42% -73.63% -58.37% -31.96% -54.82% -59.20%
Return on Common Equity (ROCE)		 0.00% 0.00% -223.15% -469.72% -97.21% -80.37% -117.42% -94.14% -48.95% -65.81% -68.81%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -300.21% -249.34% -48.60% -104.98% -95.21% -152.70% -58.61% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 0.00 0.00 -8.04 -148 -16 -20 -28 -14 -10 -7.78 -9.02
NOPAT Margin		 0.00% 0.00% -4,389.74% -71,930.07% -7,397.10% -4,331.77% -2,225.53% -394.29% -308.26% -118.08% -254.42%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% -45.41% 0.64% -10.71% -26.01% -43.93% -52.40% 11.95% -17.19% -17.33%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -72.63% -41.94% -53.72%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 3,502.67% 11,835.23% 4,679.87% 2,243.40% 1,040.89% 322.64% 225.78% 64.35% 117.99%
R&D to Revenue		 0.00% 0.00% 2,868.39% 60,194.84% 5,987.41% 4,044.85% 2,238.44% 340.64% 314.60% 204.33% 332.68%
Operating Expenses to Revenue		 0.00% 0.00% 6,371.05% 72,030.07% 10,667.28% 6,288.25% 3,279.32% 663.28% 540.37% 268.69% 463.45%
Earnings before Interest and Taxes (EBIT)		 0.00 0.00 -11 -148 -23 -29 -42 -20 -15 -11 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 0.00 0.00 -11 -148 -22 -28 -39 -20 -15 -11 -13
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 5.26 11.29 1.79 2.99 2.55 1.79 1.13 3.48 1.50 1.48
Price to Tangible Book Value (P/TBV)		 0.00 5.26 11.29 1.79 2.99 2.55 1.79 1.13 3.48 1.50 1.48
Price to Revenue (P/Rev)		 0.00 0.00 225.68 514.38 617.67 149.18 63.57 6.33 14.77 4.21 7.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% -139.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 481.58 8.06 72.59 6.04 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 197.66 214.63 411.74 103.44 28.54 2.97 10.20 1.30 2.20
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 3.79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.30 0.95 -1.32 -1.06 -2.40 -0.91 -0.91 -0.97 -0.98 -1.05 -1.02
Leverage Ratio		 -0.31 -0.96 1.33 1.07 1.05 1.29 1.59 1.61 1.53 1.20 1.16
Compound Leverage Factor		 0.00 0.00 1.27 1.07 1.00 1.28 1.59 1.59 1.48 1.15 1.11
Debt to Total Capital		 -0.25% 0.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 -0.25% 0.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.25% 99.92% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -29.67 -13.60 -32.69 9.06 24.40 -10.25 -7.65 -18.02 -27.75 -23.97 -28.12
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.24 4.56 3.40 22.11 22.83 3.81 3.56 2.14 5.57 6.36 8.39
Quick Ratio		 0.23 4.52 3.37 22.02 22.03 3.49 3.28 1.82 5.25 6.22 7.67
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 27 -26 -8.23 -147 -18 -26 -22 -15 -7.42 -8.21 -9.41
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% -9,805.72% -4,876.03% -585.34% -1,735.18% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.03 0.01 0.01 0.01 0.02 0.07 0.13 0.34 0.17
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 2.48 2.93 1.93 3.91 1.91
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 147.09 124.78 189.04 93.44 191.22
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 147.09 124.78 189.04 93.44 191.22
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -28 -1.66 -1.47 -2.41 0.18 5.99 0.49 1.73 -1.06 -0.63 -0.25
Invested Capital Turnover		 0.00 0.00 -0.12 -0.11 -0.19 0.15 0.38 3.17 9.87 -7.79 -8.06
Increase / (Decrease) in Invested Capital		 -27 26 0.19 -0.93 2.59 5.81 -5.50 1.24 -2.79 0.42 0.39
Enterprise Value (EV)		 101 25 36 44 88 48 35 10 34 8.56 7.80
Market Capitalization		 108 33 41 106 132 70 79 22 49 28 25
Book Value per Share		 ($0.33) $0.74 $0.35 $3.11 $0.96 $0.57 $0.53 $0.23 $1.58 $2.08 $1.01
Tangible Book Value per Share		 ($0.33) $0.74 $0.35 $3.11 $0.96 $0.57 $0.53 $0.23 $1.58 $2.08 $1.01
Total Capital		 -21 6.19 3.66 59 44 27 44 20 14 19 17
Total Debt		 0.05 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -6.52 -7.85 -5.13 -62 -44 -21 -43 -12 -15 -19 -17
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.15 0.37 3.42 1.57 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -28 -1.66 -1.47 -2.55 -0.41 -3.34 -10 -2.94 -1.06 -0.63 -0.25
Debt-free Net Working Capital (DFNWC)		 -21 6.19 3.66 59 43 18 33 8.84 14 19 17
Net Working Capital (NWC)		 -21 6.18 3.66 59 43 18 33 8.84 14 19 17
Net Nonoperating Expense (NNE)		 0.00 0.00 2.95 -0.21 5.66 8.49 14 16 -1.97 2.95 3.14
Net Nonoperating Obligations (NNO)		 -6.52 -7.85 -5.13 -62 -44 -21 -43 -18 -15 -19 -17
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.29 1.08 3.16 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -803.63% -1,239.69% -192.40% -716.24% -838.90% -83.81% -31.98% -9.62% -6.94%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 1,998.28% 28,735.34% 20,401.03% 3,858.11% 2,664.12% 251.53% 424.40% 281.57% 473.59%
Net Working Capital to Revenue		 0.00% 0.00% 1,998.28% 28,735.34% 20,401.03% 3,858.11% 2,664.12% 251.53% 424.40% 281.57% 473.59%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($7.80) ($3.60) ($11.60) ($7.75) $0.00 ($6.10) ($5.50) ($3.58) ($0.94) ($1.19) ($0.79)
Adjusted Weighted Average Basic Shares Outstanding		 4.39M 688.99K 945.35K 19.09M 0.00 5.07M 7.65M 8.35M 8.81M 8.98M 15.31M
Adjusted Diluted Earnings per Share		 ($7.80) ($7.20) ($11.60) ($7.75) $0.00 ($6.10) ($5.50) ($3.58) ($0.94) ($1.19) ($0.79)
Adjusted Weighted Average Diluted Shares Outstanding		 4.39M 742.10K 945.35K 19.09M 0.00 5.07M 7.65M 8.35M 8.81M 8.98M 15.31M
Adjusted Basic & Diluted Earnings per Share		 ($7.80) $0.00 ($11.60) ($7.75) $0.00 ($6.10) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.39M 843.92K 1.06M 19.09M 0.00 4.70M 8.31M 8.80M 8.90M 10.71M 16.67M
Normalized Net Operating Profit after Tax (NOPAT)		 0.00 0.00 -8.04 -104 -16 -20 -28 -14 -10 -7.78 -8.71
Normalized NOPAT Margin		 0.00% 0.00% -4,389.74% -50,351.05% -7,397.10% -4,331.77% -2,225.53% -394.29% -308.26% -118.08% -245.47%
Pre Tax Income Margin		 0.00% 0.00% -5,999.09% -71,826.32% -10,050.92% -6,149.74% -3,372.68% -562.85% -424.09% -162.06% -343.39%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -2.83% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Marker Therapeutics

This table displays calculated financial ratios and metrics derived from Marker Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 8,809,260.00 8,889,020.00 8,902,897.00 8,919,095.00 8,922,695.00 8,923,490.00 10,709,005.00 11,314,835.00 12,938,910.00 16,673,127.00 16,673,127.00
DEI Adjusted Shares Outstanding		 8,809,260.00 8,889,020.00 8,902,897.00 8,919,095.00 8,922,695.00 8,923,490.00 10,709,005.00 11,314,835.00 12,938,910.00 16,673,127.00 16,673,127.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.34 -0.32 -0.27 -0.25 -0.26 -0.43 -0.42 -0.35 -0.15 -0.10 -0.19
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -74.23% 39.17% 0.79% 53.31% 647.66% 113.13% -100.00% -26.35% -35.99% -51.00% 0.00%
EBITDA Growth		 45.08% -367.38% 40.85% 44.17% 25.01% -31.44% -80.80% -84.61% 10.97% 51.21% 27.94%
EBIT Growth		 45.08% -367.38% 40.85% 44.17% 25.01% -31.44% -80.80% -84.61% 10.97% 51.21% 27.94%
NOPAT Growth		 45.08% -287.17% 40.85% 44.17% 25.01% -31.44% -94.50% -84.61% 10.97% 51.21% 17.86%
Net Income Growth		 56.91% 27.31% 51.83% -187.16% 22.59% -36.91% -85.81% -83.14% 13.41% 55.62% 28.49%
EPS Growth		 59.04% 30.43% 52.63% -186.21% 23.53% -34.38% -48.15% -16.00% 53.85% 104.65% 60.00%
Operating Cash Flow Growth		 85.25% 62.45% 34.83% 49.44% 206.21% -98.65% -43.33% 47.35% -328.47% 59.60% 74.47%
Free Cash Flow Firm Growth		 160.71% 612.06% 234.92% -25.92% -129.38% -527.01% -160.74% 110.41% -177.90% 45.43% 94.50%
Invested Capital Growth		 -116.94% -161.21% -94.54% 62.18% -102.15% 40.12% 71.83% -169.63% 64.26% 61.20% -330.72%
Revenue Q/Q Growth		 -66.22% 310.14% 17.75% -6.01% 64.72% 16.91% -100.00% 146.68% 43.17% -10.50% -100.00%
EBITDA Q/Q Growth		 22.59% 8.20% 13.23% 9.45% -3.98% -60.90% -19.35% 7.54% 49.85% 11.83% -76.27%
EBIT Q/Q Growth		 22.59% 8.20% 13.23% 9.45% -3.98% -60.90% -19.35% 7.54% 49.85% 11.83% -76.27%
NOPAT Q/Q Growth		 22.59% 8.20% 13.23% 9.45% -3.98% -60.90% -28.39% 7.54% 49.85% 11.83% -116.17%
Net Income Q/Q Growth		 -218.53% 6.00% 14.64% 8.36% -5.27% -66.26% -15.86% 9.69% 50.23% 14.78% -86.66%
EPS Q/Q Growth		 -217.24% 5.88% 15.63% 7.41% -4.00% -65.38% 6.98% 27.50% 58.62% 116.67% -900.00%
Operating Cash Flow Q/Q Growth		 84.02% -109.99% -62.07% 7.02% 133.57% -492.75% -16.94% 65.85% -45.65% 30.55% 26.10%
Free Cash Flow Firm Q/Q Growth		 263.90% -76.00% 755.01% -137.44% 61.76% -248.85% -21.63% 106.86% -1,120.66% 31.50% 87.73%
Invested Capital Q/Q Growth		 -165.37% -38.10% 143.89% 309.27% -181.49% 59.10% 225.97% -265.85% 58.17% 55.59% -648.96%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin		 -1,242.22% -278.06% -204.89% -197.40% -124.60% -171.48% 0.00% -494.79% -173.30% -170.74% 0.00%
Operating Margin		 -1,242.22% -278.06% -204.89% -197.40% -124.60% -171.48% 0.00% -494.79% -173.30% -170.74% 0.00%
EBIT Margin		 -1,242.22% -278.06% -204.89% -197.40% -124.60% -171.48% 0.00% -494.79% -173.30% -170.74% 0.00%
Profit (Net Income) Margin		 -1,157.57% -265.31% -192.34% -187.53% -119.84% -170.43% 0.00% -466.28% -162.11% -154.35% 0.00%
Tax Burden Percent		 100.00% 102.43% 100.00% 100.00% 100.00% 101.32% 100.00% 97.16% 100.00% 28.17% 99.73%
Interest Burden Percent		 93.18% 93.15% 93.87% 95.00% 96.18% 98.09% 96.47% 97.00% 93.54% 320.97% 96.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -1,394.49% -1,920.56% -106.12% -334.97% 0.00% 0.00% 0.00% -6,460.15% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -1,390.31% -1,916.03% -99.62% -330.47% 0.00% 0.00% 0.00% -6,449.62% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 1,257.38% 1,877.82% 67.34% 295.11% 0.00% 0.00% 0.00% 6,265.09% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -137.11% -42.74% -38.78% -39.86% -80.28% -65.81% 0.00% -195.06% -110.67% -68.81% -77.04%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -20.66% -547.98% 0.00% 0.00% -1,551.74% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -123.55% -35.72% -32.38% -43.76% -44.24% -57.74% 0.00% -201.64% -49.85% -29.47% 0.00%
Return on Assets (ROA)		 -115.13% -34.08% -30.39% -41.57% -42.55% -57.38% 0.00% -190.02% -46.63% -26.64% 0.00%
Return on Common Equity (ROCE)		 -137.11% -42.74% -38.78% -39.86% -80.28% -65.81% 0.00% -195.06% -110.67% -68.81% -77.04%
Return on Equity Simple (ROE_SIMPLE)		 -55.61% 0.00% -48.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.24 -2.06 -1.78 -1.62 -1.68 -2.70 -3.47 -2.98 -1.50 -1.32 -2.85
NOPAT Margin		 -869.56% -194.64% -143.43% -138.18% -87.22% -120.04% 0.00% -346.35% -121.31% -119.52% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.17% -4.53% -6.50% -4.50% -4.75% -6.62% -7.80% -10.53% -3.60% -2.12% -2.24%
Return On Investment Capital (ROIC_SIMPLE)		 - -14.63% -15.14% -16.65% -22.55% -14.56% -23.95% -28.43% -8.13% -7.85% -20.66%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 548.38% 130.33% 97.91% 97.66% 44.38% 45.61% 0.00% 109.75% 83.04% 76.72% 0.00%
R&D to Revenue		 793.84% 247.73% 206.98% 199.74% 180.23% 225.88% 0.00% 485.04% 190.26% 194.01% 0.00%
Operating Expenses to Revenue		 1,342.22% 378.06% 304.89% 297.40% 224.60% 271.48% 0.00% 594.79% 273.30% 270.74% 0.00%
Earnings before Interest and Taxes (EBIT)		 -3.20 -2.94 -2.55 -2.31 -2.40 -3.86 -4.61 -4.26 -2.14 -1.88 -3.32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.20 -2.94 -2.55 -2.31 -2.40 -3.86 -4.61 -4.26 -2.14 -1.88 -3.32
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.39 3.48 3.25 4.99 3.38 1.50 0.91 1.65 0.63 1.48 1.57
Price to Tangible Book Value (P/TBV)		 2.39 3.48 3.25 4.99 3.38 1.50 0.91 1.65 0.63 1.48 1.57
Price to Revenue (P/Rev)		 13.27 14.77 11.53 12.99 4.66 4.21 2.46 3.21 2.46 7.00 6.11
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 58.00 21.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 7.47 10.20 8.12 10.90 3.00 1.30 0.00 1.02 0.00 2.20 1.70
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.90 -0.98 -0.68 -0.89 -1.10 -1.05 -0.95 -0.97 -1.08 -1.02 -1.04
Leverage Ratio		 1.54 1.53 1.52 1.17 1.26 1.20 1.18 1.31 1.26 1.16 1.22
Compound Leverage Factor		 1.44 1.43 1.42 1.11 1.21 1.18 1.14 1.27 1.18 3.73 1.17
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -21.87 -25.51 -32.97 -37.47 -51.92 -22.88 -33.59 -40.49 -26.49 -26.24 -33.03
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.01 5.57 6.12 5.92 3.15 6.36 6.79 3.45 6.50 8.39 4.79
Quick Ratio		 6.32 5.25 5.72 5.22 2.82 6.22 6.46 2.84 5.75 7.67 4.48
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 3.05 0.73 6.26 -2.34 -0.90 -3.13 -3.80 0.24 -2.49 -1.71 -0.21
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.10 0.13 0.16 0.22 0.36 0.34 0.34 0.41 0.29 0.17 0.21
Accounts Receivable Turnover		 3.42 1.93 2.26 1.76 13.04 3.91 2.48 2.59 3.90 1.91 1.85
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 106.84 189.04 161.26 207.41 28.00 93.44 147.11 141.06 93.66 191.22 197.39
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 106.84 189.04 161.26 207.41 28.00 93.44 147.11 141.06 93.66 191.22 197.39
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.77 -1.06 0.46 1.90 -1.55 -0.63 0.80 -1.32 -0.55 -0.25 -1.84
Invested Capital Turnover		 1.60 9.87 0.74 2.42 -4.66 -7.79 8.46 18.65 -4.46 -8.06 -6.79
Increase / (Decrease) in Invested Capital		 -5.29 -2.79 -8.05 0.73 -0.78 0.42 0.33 -3.23 1.00 0.39 -2.64
Enterprise Value (EV)		 23 34 27 41 16 8.56 -0.52 5.50 -7.39 7.80 6.04
Market Capitalization		 40 49 38 48 25 28 13 17 12 25 22
Book Value per Share		 $1.90 $1.58 $1.32 $1.09 $0.83 $2.08 $1.62 $0.93 $1.42 $1.01 $0.83
Tangible Book Value per Share		 $1.90 $1.58 $1.32 $1.09 $0.83 $2.08 $1.62 $0.93 $1.42 $1.01 $0.83
Total Capital		 17 14 12 9.70 7.45 19 14 10 18 17 14
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -17 -15 -11 -7.80 -9.00 -19 -14 -12 -19 -17 -16
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.77 -1.06 0.46 1.90 -1.55 -0.63 0.80 -1.32 -0.55 -0.25 -1.84
Debt-free Net Working Capital (DFNWC)		 17 14 12 9.70 7.45 19 14 10 18 17 14
Net Working Capital (NWC)		 17 14 12 9.70 7.45 19 14 10 18 17 14
Net Nonoperating Expense (NNE)		 0.74 0.75 0.61 0.58 0.63 1.13 0.98 1.03 0.50 0.38 0.33
Net Nonoperating Obligations (NNO)		 -17 -15 -11 -7.80 -9.00 -19 -14 -12 -19 -17 -16
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -25.44% -31.98% 14.00% 51.04% -28.73% -9.62% 14.94% -24.58% -11.80% -6.94% -51.96%
Debt-free Net Working Capital to Revenue		 554.36% 424.40% 354.98% 260.31% 138.06% 281.57% 271.03% 194.70% 391.67% 473.59% 388.98%
Net Working Capital to Revenue		 554.36% 424.40% 354.98% 260.31% 138.06% 281.57% 271.03% 194.70% 391.67% 473.59% 388.98%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.34) ($0.32) ($0.27) ($0.25) ($0.26) ($0.43) ($0.40) ($0.29) ($0.12) $0.02 ($0.16)
Adjusted Weighted Average Basic Shares Outstanding		 8.83M 8.81M 8.90M 8.92M 8.92M 8.98M 11.11M 13.96M 16.76M 15.31M 19.31M
Adjusted Diluted Earnings per Share		 ($0.34) ($0.32) ($0.27) ($0.25) ($0.26) ($0.43) ($0.40) ($0.29) ($0.12) $0.02 ($0.16)
Adjusted Weighted Average Diluted Shares Outstanding		 8.83M 8.81M 8.90M 8.92M 8.92M 8.98M 11.11M 13.96M 16.76M 15.31M 19.31M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.32) $0.00 $0.00 $0.00 ($0.43) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 8.89M 8.90M 8.92M 8.92M 8.92M 10.71M 11.31M 12.94M 16.67M 16.67M 16.67M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.24 -2.06 -1.78 -1.62 -1.68 -2.70 -3.47 -2.98 -1.50 -1.32 -2.85
Normalized NOPAT Margin		 -869.56% -194.64% -143.43% -138.18% -87.22% -120.04% 0.00% -346.35% -121.31% -119.52% 0.00%
Pre Tax Income Margin		 -1,157.57% -259.00% -192.34% -187.53% -119.84% -168.21% 0.00% -479.92% -162.11% -548.02% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Marker Therapeutics (NASDAQ: MRKR) continues to look like a development-stage biotech that is still early in the commercialization journey. The latest quarter shows the company has no product revenue yet, remains loss-making, and is burning cash, but it also ended the quarter with a stronger cash position than it had at the end of 2025.

For Q1 2026, Marker reported zero revenue and a net loss of $3.2 million, or $(0.16) per share. Operating expenses were $4.1 million, led by R&D of $2.8 million and SG&A of $1.2 million. Cash from operations was negative $1.4 million, and the company did not use investing or financing cash in the quarter.

Compared with recent history, the quarter was somewhat better than Q1 2025 on the bottom line and cash burn, but still well within the pattern of a company dependent on its balance sheet and periodic financing to fund research.

  • Cash increased from year-end 2025. Cash and equivalents rose to $14.9 million in Q1 2026 from $10.5 million in Q2 2025 and $13.7 million in Q1 2025, giving the company a better near-term liquidity cushion.
  • Operating cash burn improved versus prior quarters. Net cash used in operating activities was $1.4 million in Q1 2026, better than $1.9 million in Q4 2025 and far better than $5.5 million in Q1 2025.
  • Revenue has appeared in recent quarters after a long stretch of zero revenue. The company reported $1.1 million in Q4 2025 and $1.2 million in Q3 2025, versus no revenue in Q1 2026 and earlier periods.
  • R&D spending has come down from prior levels. Q1 2026 R&D expense of $2.8 million was below $4.2 million in Q2 2025 and $3.1 million in Q1 2025, which may help slow losses.
  • The balance sheet remains asset-light. Total assets were only $17.4 million and plant, property and equipment was essentially zero, which is typical for a clinical-stage biotech but limits operating flexibility.
  • Current liabilities are manageable for now. Total current liabilities were $3.6 million, well below current assets of $17.4 million, leaving the company with positive working capital.
  • Other income helped offset operating losses. In Q1 2026, Marker recorded $884,580 of total other income, which softened but did not eliminate the operating loss.
  • The company is still not profitable. Q1 2026 net loss was $3.2 million, following a $1.7 million loss in Q4 2025 and a $4.0 million loss in Q2 2025.
  • There is still no consistent top-line business. The latest quarter showed no revenue, and the company remains dependent on financing and/or licensing milestones rather than recurring sales.
  • Share dilution has been significant over time. Weighted average basic shares rose from roughly 8.9 million in 2024 to 19.3 million in Q1 2026, indicating substantial dilution for existing shareholders.

Bottom line: Marker Therapeutics has made some progress on cash preservation compared with earlier quarters, but it remains a high-risk biotech story. The key issue for investors is whether the company can turn recent revenue activity into a more durable financing or commercialization path before cash burn becomes a bigger concern again.

08/06/26 03:50 AM ETAI Generated. May Contain Errors.

Marker Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Marker Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

In the past 10 years, Marker Therapeutics' net income has ranged from -$41.88 million in 2021 to $0.00 in 2015, and is currently -$12.16 million as of their latest financial filing in 2025. See where experts think Marker Therapeutics is headed by visiting Marker Therapeutics' forecast page.

Marker Therapeutics' total operating income in 2025 was -$12.89 million, based on the following breakdown:
  • Total Gross Profit: $3.55 million
  • Total Operating Expenses: $16.44 million

Over the last 10 years, Marker Therapeutics' total revenue changed from $0.00 in 2014 to $3.55 million in 2025, a change of 354,666,900.0%.

Marker Therapeutics' total liabilities were at $2.27 million at the end of 2025, a 34.4% decrease from 2024, and a 82.2% increase since 2014.

In the past 10 years, Marker Therapeutics' cash and equivalents has ranged from $141.94 thousand in 2014 to $43.90 million in 2019, and is currently $16.07 million as of their latest financial filing in 2025.

Over the last 10 years, Marker Therapeutics' book value per share changed from -0.33 in 2015 to 1.01 in 2025, a change of -404.7%.


Related Companies

Financial statements for NASDAQ:MRKR last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Control 100 shares without spending thousands of dollars
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
A $5 stock inside Kennedy Space Center?
A small publicly traded company operates a specialized launch vehicle fleet inside the secure perimeter of Ken...
Freedom Financial | Sponsoredtc pixel
A Secret Plan to End Trump in November?
A White House insider with close ties to the Trump family is speaking out about what he calls the biggest poli...
Paradigm Press | Sponsoredtc pixel
ALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.
Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's ...
Brownstone Research | Sponsoredtc pixel